AN2 Therapeutics, Inc.
AN2 Therapeutics is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics based on their boron chemistry platform. They have a pipeline of boron-based compounds in development for Chagas disease, melioidosis, and NTM lung disease caused by M. abscessus, along with programs focused on targets in oncology and infectious diseases. AN2 is committed to delivering high-impact drugs to patients with critical unmet needs and improving health outcomes.
Registro Oficial
Análisis de Calidad IA
Desglose de Puntuación de Confianza
Enlaces Rápidos
Destacados del sitio web
🌟 Empresas similares de confianza
Kalaris Therapeutics, Inc.
Kalaris is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases. They focus on innovative retinal treatments, including TH103, a potential best-in-class anti-VEGF agent for neovascular AMD. Kalaris aims to ease patient burden and improve outcomes in retinal disease management.
Vor Biopharma Inc.
Vor Bio is a biopharmaceutical company focused on reinventing autoimmune disease treatment by targeting its root causes. Their lead program, telitacicept, is a potential first-in-class dual BAFF/APRIL inhibitor designed to silence survival signals of harmful B cells, aiming to halt autoantibody production. Vor Bio is committed to advancing transformative therapies that move beyond symptom control. They aspire to become a global leader in targeted autoimmune disease therapeutics.
PUMA BIOTECHNOLOGY, INC.
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer. They focus on in-licensing innovative drug candidates that have undergone clinical testing. Puma Biotechnology aims to improve cancer treatment through innovative drug development.